CoChat

Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos

Open access
Alanis-Lobato, Gregorio, Zohren, Jasmin, McCarthy, Afshan, Fogarty, Norah M. E., Kubikova, Nada, Hardman, Emily, Greco, Maria, Wells, Dagan, Turner, James M. A., Niakan, Kathy K. · 2021 · Proceedings of the National Academy of Sciences

Published version of a preprint

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index; 35 of the 46 sources its claims cite were checked for support.

Abstract

CRISPR-Cas9 genome editing is a promising technique for clinical applications, such as the correction of disease-associated alleles in somatic cells. The use of this approach has also been discussed in the context of heritable editing of the human germ line. However, studies assessing gene correction in early human embryos report low efficiency of mutation repair, high rates of mosaicism, and the possibility of unintended editing outcomes that may have pathologic consequences. We developed computational pipelines to assess single-cell genomics and transcriptomics datasets from OCT4 ( POU5F1 ) CRISPR-Cas9–targeted and control human preimplantation embryos. This allowed us to evaluate on-target mutations that would be missed by more conventional genotyping techniques. We observed loss of heterozygosity in edited cells that spanned regions beyond the POU5F1 on-target locus, as well as segmental loss and gain of chromosome 6, on which the POU5F1 gene is located. Unintended genome editing outcomes were present in ∼16% of the human embryo cells analyzed and spanned 4–20 kb. Our observations are consistent with recent findings indicating complexity at on-target sites following CRISPR-Cas9 genome editing. Our work underscores the importance of further basic research to assess the safety of genome editing techniques in human embryos, which will inform debates about the potential clinical use of this technology.

Overview

CoChat Summary

TL;DR

Reanalysis of single-cell genomics and transcriptomics from CRISPR-Cas9–edited early human embryos found frequent loss-of-heterozygosity and segmental chromosome 6 abnormalities near the POU5F1 on-target site. The authors conclude that unintended on-target damage can be missed by conventional short-fragment genotyping and caution against clinical germline editing.

Key findings

  • In low-pass WGS of 65 samples (25 CRISPR-Cas9 targeted, 16 Cas9 controls, 24 uninjected controls), 8/25 targeted samples had chromosome 6 abnormalities: 4 had segmental loss/gain adjacent to or within POU5F1 (16%) and 4 had whole chromosome 6 gain (16%). One Cas9 control (6.25%) had a segmental gain on 6q distinct from POU5F1, and no uninjected controls showed abnormalities; targeted vs Cas9 P = 0.0144 and targeted vs uninjected P = 0.0040 by two-tailed Fisher’s test.
  • Targeted deep sequencing of 137 single cells/clusters (111 targeted, 26 Cas9 controls; 42 targeted and 10 controls retained after filtering) found open-ended LOH in 61.9% of targeted vs 10% of control samples, bookended LOH in 23.8% targeted vs 20% control, LOH at the locus in 2.4% targeted vs 50% control, and no LOH in 11.9% targeted vs 20% control. LOH events spanned 4 kb to at least 20 kb.
  • Transcriptome analyses did not show preferential misexpression of chromosome 6 genes or genes telomeric to POU5F1, and transcriptome-based digital karyotyping/eSNP-Karyotyping did not confirm the gDNA-derived chromosome 6 trends.

Methods

  • The study reprocessed DNA and reanalyzed data from a previous study plus 56 additional samples. Human in vitro fertilized zygotes donated as surplus to infertility treatment were microinjected with sgRNA-Cas9 ribonucleoprotein targeting POU5F1 exon 2 or Cas9 protein alone, cultured 5–6 days, and single cells or 2–5-cell clusters were collected.
  • Low-pass whole-genome sequencing (<0.1×) was used for copy-number profiles; targeted deep sequencing used 15 PCR amplicons spanning a ~20 kb POU5F1 region plus an ARGFX control on chromosome 3, with SNP calling and allele-overamplification correction. Single-cell RNA-seq data were analyzed with DESeq2, z-score-karyotyping, and eSNP-Karyotyping.
  • Comparisons of abnormality frequencies used two-tailed Fisher’s tests.

Limitations

  • The paper states that shallow sequencing, MDA-amplified gDNA, and lack of parental genotypes may cause overestimation of LOH events; it also notes that inherited homozygous genotypes cannot be excluded without parental genotypes.
  • The authors state that mosaicism is common in human preimplantation embryos, so abnormalities in one analyzed cell may not represent the whole embryo.
  • The paper notes that transcriptome and cytogenetics data were not from the same samples, and that single-cell WGA is prone to allele over-amplification and allelic dropout, which can confound interpretation of on-target complexity.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.2004832117

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

30 Valid · 1 Not valid · 6 Not checked · 71 Own results and interpretations

52 more claims · 4 with their cited sources checked

Create a free account to see all 108 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 31
  • It may state two separate claims as one. 23
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 66 references

Research works printed but not linked: 2

  1. N. M. Fogarty . Uncovering mechanisms of early human lineage specification by CRISPR/Cas9-mediated genome editing [RNA-seq]. Gene Expression Omnibus . https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100118. Accessed 10 September 2020.
  2. G. Alanis-Lobato . Frequent loss-of-heterozygosity in CRISPR-Cas9-edited early human embryos. GitHub. https://github.com/galanisl/loh_scripts. Deposited 31 May 2020. · DOI

Cited by

See all 234

Metadata

Authors
Alanis-Lobato, G., Zohren, J., McCarthy, A., Fogarty, N. M. E., Kubikova, N., Hardman, E., Greco, M., Wells, D., Turner, J. M. A., & Niakan, K. K.
Affiliations
  • Human Embryo and Stem Cell Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom;
  • The Francis Crick Institute (GB)
  • King's College London (GB)
  • John Radcliffe Hospital (GB)
  • University of Cambridge (GB)
Venue
Proceedings of the National Academy of Sciences
Published
2021-04-09
Volume
118
Issue
22
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3154289394
Cited by
234
References
57
Citations by year
2026: 24 · 2025: 29 · 2024: 40 · 2023: 56 · 2022: 45 · 2021: 29
FWCI
11.91
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • Cancer Research UK (FC001120, FC001193)
  • RCUK | Medical Research Council (FC001120, FC001193)
  • Wellcome (FC001120, FC001193)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
CRISPR/Cas9 genome editing, human embryo, loss of heterozygosity, Oct4, preimplantation embryo, mosaicism, off-target editing, chromosome 6, germline editing, single-cell genomics, single-cell transcriptomics, computational pipeline, genome editing safety
MeSH terms
Human Embryonic Stem Cells, Gene Editing, Blastocyst, Cell Line, Chromosomes, Human, Pair 6, Humans, Loss of Heterozygosity, Octamer Transcription Factor-3, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos. https://app.cochat.ai/papers/10.1073/pnas.2004832117
The paper
Alanis-Lobato, G., Zohren, J., McCarthy, A., Fogarty, N. M. E., Kubikova, N., Hardman, E., Greco, M., Wells, D., Turner, J. M. A., & Niakan, K. K. (2021). Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2004832117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.